BioSpace News Archive

Honored for the development of a method for genome editing, Scribe co-founder and scientific advisor Jennifer Doudna continues to advance breakthroughs in CRISPR and genetic medicine

Finch Therapeutics Group, Inc. (“Finch”), a clinical-stage microbiome drug development company, announced today that data from its positive PRISM3 trial with CP101, an investigational oral microbiome drug, were accepted as late-breaking abstracts for oral presentation at the United European Gastroenterology Week (UEGW) and the American College of Gastroenterology (ACG) Annual Scientific Meeting,

Tricida, Inc. (Nasdaq: TCDA), veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it has authored or sponsored 12 presentations at the upcoming American Society of Nephrology (ASN) Kidney Week 2020 being held virtually October 22-25, 2020.

As healthcare facilities look for new and innovative ways to battle multi-drug resistant organisms that can pose a risk to patient safety, Urosurgical Center of Richmond has taken a leap into the future with a LightStrike Germ-Zapping Robot named Rosie that destroys hard-to-kill viruses, bacteria and superbugs in hard-to-clean places.

M-LIFE™ has identified 8 drugs as prospective repurposing targets to address the cytokine storm associated with severe COVID-19 cases.

Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnology initiatives, today announced that it has retained Federal Award Management Registration (“FAMR”) to commence the bid

Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming data presentations at ASN’s Kidney Week 2020 Reimagined from October 22-25, 2020.

The University of Tokyo and Eisai Co., Ltd. announced today a collaboration aiming for the development and drug discovery of targeted protein degradation technology has been created, with the establishment of a social cooperation program, “Protein Degradation Drug Discovery”.

The Parkinson Foundation of the National Capital Area (PFNCA) will host its annual awareness and fundraising walk – Walk Off Parkinson’s – virtually on Oct. 14 and Oct. 20 , 2020. The program, which starts at 6:30 p.m. ET each day, features educational and inspirational content from 18 doctors who are Movement Disorder Specialists

Platform measures changes in H3K4me3 histone modifications to predict optimal growth factors required to both maintain cells in culture and support conversion between cell types EpiMOGRIFY co-developed and co-owned by Duke-NUS, Monash University and Mogrify Company’s platforms support the development of scalable off-the-shelf cell therapies for diseases with a